Peera BuranakitjaroenSurachai SaravichMeta PhoojaroenchanachaiPantip SangprasertMahidol University2018-07-242018-07-242002-09-01Journal of the Medical Association of Thailand. Vol.85, No.9 (2002), 968-977012522082-s2.0-0036764277https://repository.li.mahidol.ac.th/handle/20.500.14594/20394This open-labeled single-blinded study was performed to evaluate the efficacy and tolerability of telmisartan in the treatment of mild to moderate essential hypertension. Each patient was assigned to take a placebo for 4 weeks followed by once daily-titrated telmisartan (40-80 mg) for 8 weeks. "Office BP" and "24-hour ambulatory BP" measurements (24-h ABPM) were recorded as scheduled. Thirty-one patients (10 males: 21 females) with a mean age of 48.1 years were enrolled. The final SBP/DBP reductions of 14.6 ± 14.2/9.9 ± 6.2 mm Hg were obtained. Full response defined as office DBP reduction of ≥10 mm Hg from baseline and/or DBP <90 mm Hg was achieved in 73.3 per cent of cases. Excluding 5 cases of white coat HT diagnosed by 24-h ABPM, full response rate (DBP reduction of ≥10 mm Hg from baseline and/or <85 mm Hg) was 76 per cent. Trough to peak ratio and smoothness index for SBP/DBP were highly acceptable (0.75/0.76 and 0.97/1.01, respectively). There were 4 cases of adverse events (2 cases of dizziness, 1 case of headache, and 1 case of acute myocardial infarction).Mahidol UniversityMedicineArticleSCOPUS